Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Celgene reports preliminary results, guidance

Celgene (NASDAQ:CELG) said it expects 2007 adjusted diluted EPS to double to $1.05 and 2007 revenue to rise more

Read the full 197 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE